Liver Function Tests
Breaking Through Conventional Thinking About Liver Health Testing
HepQuant’s innovative, noninvasive tests of liver function and physiology provide patients, investigators, care providers, and payers with a dynamic and comprehensive Picture of Liver Health.
HepQuant is a privately-held, early-stage medical diagnostics company with unique, patented and patent-pending technology for assessing liver function of patients with chronic liver disease. HepQuant technologies, licensed from the University of Colorado Denver (UCD), have been advanced with the intent to profoundly impact the liver disease landscape – including the research, treatment and patient communities – with diagnostic products that are accurate and minimally invasive.
Liver Testing for Pharma Trials, Liver Research Trials
Through its Investigational Device Exemption (IDE), HepQuant provides liver testing support services to liver research centers and pharmaceutical companies. The HepQuant tests are designed to evaluate the liver — and levels of hepatic impairment — regardless of the etiology of the liver disease. Specifically, the tests establish a Disease Severity Index score by measuring hepatic blood flow, portal blood flow, and portal-systemic shunt in patients suffering from chronic liver disease (CLD).
Recent News
- May 22 – Hepion Pharmaceuticals’ Phase 2 ‘ALTITUDE-NASH’ Trial Achieves Primary and Secondary Endpoints, Including Improvement in Liver Function and Multiple NASH Biomarkers
- Jan. 23 – HepQuant Lab Moves to New Location Within Fitzsimons Innovation Community Campus
- Dec. 5 – Hepion Pharmaceuticals Announces Early Completion of Enrollment in Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial
- Oct. 28 – HepQuant Named One of Colorado’s Best Health Diagnostics Companies | Best Startups
- Sep. 12 – Hepion Announces First Dosing in Phase 2b Clinical Trial with HepQuant Endpoints
- Aug. 24 – HepQuant Lab Meets COLA – CLIA Quality Standards
- June 2 – Tackling Liver Disease with a Multimodal Cyclophilin Inhibitor | pharma’s almanac
Recent Publications
- “As it awaits key readout, Hepion boosts confidence in NASH drug hopeful via shorter study” | Endpoint News | May 22, 2023
- How clinicians may use tests of hepatic function now and in the future | T. Tara Ghaziani, Paul Y. Kwo | Translational Research (formerly The Journal of Laboratory and Clinical Medicine) | July 1, 2021
The HepQuant Story | Where We’ve Been, Where We’re Going
Upcoming Events
♦ EASL 2023 | Vienna, Austria | June 21-23, 2023 | Two Data Point Presentations
Recent Events
♦ Fourth Annual HCC-TAG Conference Poster Presentation | Huntington Beach, CA | Feb. 23-25, 2023
♦ Program Partner sponsor at Obesity & NASH Drug Development Summit | Boston, MA | Nov. 29-Dec. 1, 2022 |
- Presentation: “Moving the Needle (Literally) in Drug Development“
♦ AASLD – The Liver Meeting 2022 | Washington, DC | November 4-8, 2022 | Posters:
♦ Presented at The Rocky Mountain Life Science Investor and Partnering Conference | Vail, CO | Sep. 13-14, 2022
♦ The American College of Clinical Pharmacology® (ACCP) Annual Meeting, Sept 25-27th, 2022 in Bethesda, MD | Poster: Advantages of HepQuant SHUNT over Child-Pugh Classification in Defining Hepatic Impairment for Pharmacokinetics Studies: Experience with Ampreloxetine
♦ EASL International Liver Congress™ 2022 | June 22–26, 2022 | Poster: A multi-compartmental model of the HepQuant SHUNT test quantifies anatomic shunting and stratifies risk for varices: combined results from the HALT-C and SHUNT-V studies
♦ Digestive Disease Week | May 21 – 24, 2022 | HepQuant abstracts accepted:
- The HepQuant’s Disease Severity Index (HepQuant DSI™) Outperforms Child-Pugh (CP) Classification in Quantifying Hepatic Impairment for Prediction of Drug Pharmacokinetics (PK) in Chronic Liver Disease (Poster)
- The HepQuant Shunt Disease Severity Index (HepQuant DSI™) Can Aid the Decision to Avoid Endoscopic Screening or Surveillance for Varices Needing Treatment (Poster)
♦ 40th Annual J.P. Morgan HealthCare Conference | January 10 – 13, 2022 | San Francisco, CA
♦ NASH-TAG Conference | January 6 – 8, 2022
- Poster Presentation: HMG-CoA Reductase Inhibitors (Statins) and Metformin are Associated With Preservation of Hepatic Function and Less Portal-Systemic Shunting in Advanced Chronic Liver Disease (CLD)
♦ NASH Summit 2021 | November 29-December 2, 2021 | Sponsor
- Oral Presentation: HepQuant: Progressing towards a Sensitive and Reliable Endpoint for Treatment Efficacy. Greg Everson, MD.
- New Data from Clinical Trials (response to new pharma therapy, reproducibility, progression to decomp in cirrhosis, portal hypertension)
- Pivotal Study and Regulatory Progress
- Anticipated Timelines for Clinical Trial and Commercial Scale-up
CONTACT US
These images and links are for informational purposes only and do not imply that HepQuant has any formal relationships with the organizations, nor do the organizations endorse HepQuant or its liver function tests.